Literature DB >> 9863018

Mutation analysis of transforming growth factor beta type II receptor, Smad2, and Smad4 in hepatocellular carcinoma.

S Kawate1, S Takenoshita, S Ohwada, A Mogi, T Fukusato, F Makita, H Kuwano, Y Morishita.   

Abstract

Mutations in the transforming growth factor beta type II receptor (TGFbetaRII), Smad2, and Smad4 genes have been detected in several human cancers. However, there are no reports of mutation analysis of the entire coding regions in these genes in hepatocellular carcinoma, and the roles of these genes in hepatocarcinogenesis remain unknown. We screened 30 hepatocellular carcinomas for mutations of these genes using polymerase chain reaction single-strand conformation polymorphism. We detected no mutations, but did find 3 cases of loss of heterozygosity of chromosome 17p13.1. These results suggest that mutations of the TGFbetaRII, Smad2, and Smad4 genes are rare, and that genetic instability is uncommon in human hepatocellular carcinoma.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9863018     DOI: 10.3892/ijo.14.1.127

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  12 in total

1.  Hemizygous deletion and hypermethylation of RUNX3 gene in hepatocellular carcinoma.

Authors:  Wen-Hua Xiao; Wei-Wen Liu
Journal:  World J Gastroenterol       Date:  2004-02-01       Impact factor: 5.742

Review 2.  Smad3 phospho-isoform signaling in hepatitis C virus-related chronic liver diseases.

Authors:  Takashi Yamaguchi; Katsunori Yoshida; Miki Murata; Koichi Matsuzaki
Journal:  World J Gastroenterol       Date:  2014-09-21       Impact factor: 5.742

3.  Deletion of Smad2 in mouse liver reveals novel functions in hepatocyte growth and differentiation.

Authors:  Wenjun Ju; Atsushi Ogawa; Joerg Heyer; Dirk Nierhof; Liping Yu; Raju Kucherlapati; David A Shafritz; Erwin P Böttinger
Journal:  Mol Cell Biol       Date:  2006-01       Impact factor: 4.272

4.  Factors of transforming growth factor beta signalling are co-regulated in human hepatocellular carcinoma.

Authors:  Thomas Longerich; Kai Breuhahn; Margarete Odenthal; Katharina Petmecky; Peter Schirmacher
Journal:  Virchows Arch       Date:  2004-09-29       Impact factor: 4.064

5.  Downregulation of the adenosine a2b receptor by RNA interference inhibits hepatocellular carcinoma cell growth.

Authors:  Hong-Jun Xiang; Fu-Lu Chai; De-Sheng Wang; Ke-Feng Dou
Journal:  ISRN Oncol       Date:  2011-04-28

Review 6.  Transforming growth factor-beta and breast cancer: Transforming growth factor-beta/SMAD signaling defects and cancer.

Authors:  M Kretzschmar
Journal:  Breast Cancer Res       Date:  2000-02-21       Impact factor: 6.466

7.  Alterations of the transforming growth factor-beta signaling pathway in hepatocellular carcinomas induced endogenously and exogenously in rats.

Authors:  Y Sasaki; T Tsujiuchi; N Murata; M Tsutsumi; Y Konishi
Journal:  Jpn J Cancer Res       Date:  2001-01

Review 8.  Smad4-mediated TGF-beta signaling in tumorigenesis.

Authors:  Guan Yang; Xiao Yang
Journal:  Int J Biol Sci       Date:  2010-01-01       Impact factor: 6.580

Review 9.  Human hepatocyte carcinogenesis (review).

Authors:  Hidenori Shiraha; Kazuhide Yamamoto; Masayoshi Namba
Journal:  Int J Oncol       Date:  2013-02-19       Impact factor: 5.650

10.  TGF-β signaling is often attenuated during hepatotumorigenesis, but is retained for the malignancy of hepatocellular carcinoma cells.

Authors:  Xiaoxin Mu; Shu Lin; Junhua Yang; Chen Chen; Yun Chen; Maryanne C Herzig; Kenneth Washburn; Glenn A Halff; Christi A Walter; Beicheng Sun; Lu-Zhe Sun
Journal:  PLoS One       Date:  2013-05-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.